Curtis Jackson was enjoying good health in late 2020 when he decided to update his life insurance policy to ensure his family's security. However, during a routine screening, doctors found something alarming.

At 46 years old, Jackson underwent a thorough physical examination that revealed concerning liver numbers. Despite not drinking alcohol, his results resembled those of a heavy drinker, prompting further investigation.

Following a strange phone call, Jackson's primary care physician suspected a gallbladder issue. However, during surgery to remove his gallbladder, doctors discovered he had primary sclerosing cholangitis (PSC), a chronic liver disease that can lead to a rare and deadly cancer known as cholangiocarcinoma.

Early detection is crucial, so Jackson began regular monitoring at the Mayo Clinic in Arizona. In October 2024, a concerning appointment hinted at a potential cancer diagnosis. Three weeks later, the news was confirmed: Jackson had cholangiocarcinoma.

Cholangiocarcinoma is a silent killer that often spreads before symptoms manifest, making it difficult to treat. Approximately 20% of PSC patients develop this rare cancer, affecting only about 1 in 100,000 people in the U.S. While a liver transplant is the best treatment, many patients are ineligible.

Fortunately, Jackson's cancer was caught early. After three weeks of intense treatment, including chemotherapy and radiation, he underwent a successful liver transplant in March 2025.

Post-surgery, Jackson is cancer-free but requires ongoing monitoring. Despite some physical limitations, he is grateful for his recovery and looks forward to normalcy, family time, and advocacy for organ donation.